Profund Advisors LLC Decreases Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Profund Advisors LLC lessened its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 11.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,987 shares of the company’s stock after selling 2,442 shares during the quarter. Profund Advisors LLC’s holdings in Vaxcyte were worth $1,434,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Vaxcyte by 15.2% during the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after buying an additional 1,284,883 shares in the last quarter. RA Capital Management L.P. increased its position in shares of Vaxcyte by 4.0% during the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock worth $560,398,000 after acquiring an additional 312,500 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock worth $524,117,000 after buying an additional 692,492 shares during the period. Capital Research Global Investors grew its holdings in Vaxcyte by 20.4% during the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after acquiring an additional 700,414 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Vaxcyte by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock valued at $216,966,000 after purchasing an additional 498,359 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Activity at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 3,000 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $76.34, for a total transaction of $229,020.00. Following the completion of the transaction, the chief operating officer now owns 210,503 shares of the company’s stock, valued at $16,069,799.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, SVP Mikhail Eydelman sold 1,667 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $76.37, for a total transaction of $127,308.79. Following the completion of the sale, the senior vice president now owns 30,826 shares of the company’s stock, valued at approximately $2,354,181.62. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Jim Wassil sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $76.34, for a total transaction of $229,020.00. Following the completion of the transaction, the chief operating officer now directly owns 210,503 shares in the company, valued at $16,069,799.02. The disclosure for this sale can be found here. In the last three months, insiders have sold 78,283 shares of company stock valued at $7,064,138. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Price Performance

Shares of PCVX stock opened at $112.11 on Tuesday. Vaxcyte, Inc. has a 1-year low of $44.20 and a 1-year high of $121.06. The company has a market cap of $12.20 billion, a price-to-earnings ratio of -26.19 and a beta of 0.97. The stock has a 50 day simple moving average of $89.68 and a 200-day simple moving average of $76.70.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same quarter in the previous year, the company earned ($0.70) EPS. Analysts anticipate that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PCVX has been the subject of several research analyst reports. Mizuho increased their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Thursday, June 20th. Leerink Partners raised their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 3rd. BTIG Research boosted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Jefferies Financial Group increased their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.